Glecaprevir

• Description :

  Glecaprevir is a novel HCV NS3/4A protease inhibitor, with IC50 values ranging from 3.5 to 11.3 nM. Glecaprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 4.09 μM[2].

• Product Name Alternative :

  ABT-493

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  HCV; HCV Protease; SARS-CoV

• Type :

  Reference compound

• Related Pathways :

  Anti-infection; Metabolic Enzyme/Protease

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Infection

• Assay Protocol :

  https://www.medchemexpress.com/Glecaprevir.html

• Purity :

  99.93

• Solubility :

  DMSO : ≥ 83.3 mg/mL

• Smiles :

  O=C([C@H]1N(C([C@@H](NC(O[C@@]2([H])[C@@]3([H])CCC2)=O)C(C)(C)C)=O)C[C@@](OC4=NC5=CC=CC=C5N=C4C(F)(/C=C/CO3)F)([H])C1)N[C@]6([C@H](C(F)F)C6)C(NS(=O)(C7(CC7)C)=O)=O

• Molecular Formula :

  C38H46F4N6O9S

• Molecular Weight :

  838.87

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Ng TI, et al. In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir. Antimicrob Agents Chemother. 2017 Oct 30. pii: AAC.01620-17.|[2]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6 (1) :212.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• CAS Number :

  [1365970-03-1]